This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CHFS Nuwellis (CHFS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock About Nuwellis Stock (NASDAQ:CHFS) Get Nuwellis alerts:Sign Up Key Stats Today's Range$3.40▼$3.5150-Day Range$3.53▼$6.0252-Week Range$4.86▼$37.50Volume25,005 shsAverage Volume467,323 shsMarket Capitalization$20.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN. Read More Receive CHFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CHFS Stock News HeadlinesNuwellis Secures New Patent for Hemolysis SensorsSeptember 18, 2025 | tipranks.comNuwellis Secures NIH Grant for Pediatric Device DevelopmentSeptember 9, 2025 | tipranks.comNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.October 16 at 2:00 AM | InvestorPlace (Ad)Nuwellis Gains FDA Clearance for New CatheterAugust 21, 2025 | tipranks.comNuwellis Approves Stock Proposals at Special MeetingAugust 4, 2025 | tipranks.comNuwellis Regains Nasdaq Compliance After Delisting RiskJuly 23, 2025 | tipranks.comNuwellis Appoints John L. Erb as CEOJuly 2, 2025 | tipranks.comNuwellis, Inc. Reports Modest Growth and Strategic ExpansionMay 13, 2025 | tipranks.comSee More Headlines CHFS Stock Analysis - Frequently Asked Questions How were Nuwellis' earnings last quarter? Nuwellis, Inc. (NASDAQ:CHFS) announced its earnings results on Monday, March, 1st. The company reported ($1.57) earnings per share for the quarter, beating the consensus estimate of ($1.91) by $0.34. The firm had revenue of $2.04 million for the quarter. Nuwellis had a negative trailing twelve-month return on equity of 173.61% and a negative net margin of 254.26%. When did Nuwellis' stock split? Shares of Nuwellis reverse split on the morning of Friday, October 13th 2017.The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 12th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Nuwellis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuwellis investors own include Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Biocept (BIOC), VBI Vaccines (VBIV), Prima BioMed (IMMP), NightHawk Biosciences (NHWK) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings3/01/2021Today10/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical Equipment Sub-IndustryN/A Current SymbolNASDAQ:CHFS Previous SymbolNASDAQ:SSH CIK1506492 Webwww.chf-solutions.com Phone(952) 345-4200FaxN/AEmployees66Year FoundedN/AProfitability EPS (Trailing Twelve Months)($279.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.11 million Net Margins-254.26% Pretax MarginN/A Return on Equity-173.61% Return on Assets-131.01% Debt Debt-to-Equity RatioN/A Current Ratio6.87 Quick Ratio5.97 Sales & Book Value Annual Sales$5.51 million Price / Sales3.80 Cash FlowN/A Price / Cash FlowN/A Book Value$12.79 per share Price / Book0.27Miscellaneous Outstanding Shares6,037,000Free FloatN/AMarket Cap$20.95 million OptionableNot Optionable Beta1.55 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CHFS) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuwellis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuwellis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
